Author(s): Merriweather N, SulzbachHoke LM
Abstract Share this page
Abstract Percutaneous coronary intervention for acute coronary syndrome or non-ST-elevation myocardial infarction requires the use of potent oral and intravenous anti-platelet and antithrombin medications. Although these potent antithrombotic agents and regimens may increase the effectiveness of percutaneous coronary intervention, they are also generally associated with an increased risk of vascular access complications such as hematoma, retroperitoneal hematoma, pseudoaneurysm, arterial occlusion, and arteriovenous fistula, which in turn are associated with increased morbidity, mortality, and costs. Risk factors predisposing patients to these complications are both modifiable (procedure technique, medications, hemostasis method) and nonmodifiable (sex, age, body mass index, blood pressure, renal function). Patients' risks can be reduced by nurses who are knowledgeable about these risk factors and identify complications before they become problematic.
This article was published in Crit Care Nurse
and referenced in Journal of Vascular Medicine & Surgery
- Ishfaq A Bukhari
Protective Effect of Diltiazem and Fenofibrate Against Ischemia-reperfusion Induced Cardiac Arrhythmias in the Isolated Rat Heart.
PPT Version | PDF Version
- Zamaneh Kassiri
Loss of tissue inhibitor of metalloproteinase-3 (Timp3) leads to abdominal aortic aneurysm (AAA)
- Antonio Ferrari
Spontaneous Ventricular Arrhythmias in Early Clinical Trials A Report from a Single and Repeated Ascending Dose Study
- Mohamed Chahine
A novel mechanism of an SCN5A mutation causing mixed arrhythmias associated with dilated cardiomyopathy
- Saverio Gentile
Ion channels phosphorylopathy: 3rd International Conference on Clinical & Experimental Cardiology April 15-17, 2013 A link between genomic variations and heart arrhythmia